• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Impel NeuroPharma raises $68m for CNS drug-device tech

December 6, 2018 By Sarah Faulkner

Impel Neuropharma logo updatedImpel NeuroPharma said today that it raised $67.5 million in a Series D financing round, with investments from KKR, Norwest Venture Partners, Vivo Capital, 5Am Ventures and venBio Partners.

The Seattle-based company plans to use the round’s proceeds to support clinical development efforts for its intranasal drug-delivery device technology.

Impel’s INP104 product is in a Phase III trial for the treatment of acute migraine headache. The company also has a product in a Phase II trial for the reversal of “off” periods in people with Parkinson’s disease, as well as a product in a Phase I trial for the treatment of acute agitation in bipolar I and schizophrenia disorders.

Dr. Robert Mittendorff, a partner at Norwest, and Ali Satvat, a member at KKR, plan to join Impel’s board of directors in connection with the financing round.

“We are delighted to have the support of this exceptional group of both new and existing investors. Dr. Mittendorff and Mr. Satvat will be tremendous assets as new members of Impel’s Board of Directors and we believe that this investment is a testament to the strength of our POD technology, our clinical programs and our management team,” CEO Jon Congleton said in prepared remarks.

“With three product candidates progressing through various stages of clinical development in 2018, it has been an exciting year for Impel, and this financing confirms the value that we are generating with our clinical programs,” Congleton added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Neurological, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS